Blood Disorders & Hematology Clinical Trials Update: Week 17, 2026

Published April 24, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

This Phase 3 trial is testing mocravimod as an additional treatment for adults with acute myeloid leukemia (AML) who are undergoing an allogeneic stem cell transplant. The goal is to see if mocravimod can reduce the risk of the leukemia coming back after transplant and improve survival rates. The study is currently recruiting patients in several countries, offering hope for a new way to support recovery after this intense treatment.

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

This Phase 3 study compares two drug combinations for adults with relapsed or refractory multiple myeloma, a type of blood cancer that has returned or not responded to treatment. One combination includes belantamab mafodotin, while the other uses daratumumab, both paired with bortezomib and dexamethasone. Results from this trial, which is active but not recruiting, may lead to new options that improve outcomes for patients facing this challenging disease.

A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects

This Phase 3 trial is focused on children aged 2 to under 18 years old who have iron deficiency anemia, a common condition where the body lacks enough iron. It compares two treatments, ferumoxytol and iron sucrose, to see which works better and is safer for young patients. The study is currently recruiting in multiple countries including the United States and aims to provide clearer choices for managing anemia in children after five weeks of treatment.

Azacitidine + Venetoclax VS Azacitidine as Maintenance Therapy in AML

This Phase 3 trial is testing whether adding venetoclax to azacitidine improves maintenance therapy for patients with acute myeloid leukemia (AML) who are in remission. Maintenance therapy helps keep the disease from returning after initial treatment. The study is enrolling a large group of patients aged 14 to 74 and may offer new ways to extend remission and improve survival for people with AML.

China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

This trial is the China-specific part of the study comparing belantamab mafodotin with daratumumab in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. Although not currently recruiting, it has produced results that help tailor treatments for patients in China, potentially improving care options for this difficult-to-treat blood cancer.

This week saw important progress in blood disorders and hematology, with several trials focusing on improving treatments for leukemia, multiple myeloma, and iron deficiency anemia, especially in children and transplant patients. These studies represent ongoing efforts to find safer, more effective options that can help patients live longer and healthier lives. TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.